I attended the Annual General Meeting of Abcam yesterday (3/11/2014) at their offices in Cambridge. Abcam primarily sells antibodies via the internet to research scientists worldwide. They are one of the more successful AIM companies, with consistent profitability, good growth and good cash flow. But the pace of growth has been slowing of late and last year was somewhat disappointing. This may be due to pressure on Government spending, which finances most scientific research, in the USA and other countries. The ...